

List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6943477/luca-arcaini-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

279 papers	13,028 citations	59 h-index	111 g-index
298 ext. papers	15,083 ext. citations	4.5 avg, IF	5.55 L-index

#	Paper	IF	Citations
279	MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 826-33	59.2	896
278	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2305-15	59.2	791
277	Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7594-603	2.2	678
276	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1389-401	16.6	483
275	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4555-62	2.2	483
274	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 755-61	2.4	355
273	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , <b>2013</b> , 121, 2051-8	2.2	298
272	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1537-51	16.6	289
271	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 229-240	40	283
270	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. <i>Leukemia</i> , <b>2010</b> , 24, 1574-9	10.7	261
269	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , <b>2011</b> , 117, 3391-401	2.2	249
268	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. <i>Blood</i> , <b>2013</b> , 121, 2522-8	2.2	229
267	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , <b>2013</b> , 24, 857-77	10.3	225
266	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology, the</i> , <b>2020</b> , 7, e737-e745	14.6	223
265	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. <i>Blood</i> , <b>2006</b> , 107, 3676-82	2.2	214
264	Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 468-73	2.2	211
263	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. <i>Haematologica</i> , <b>2008</b> , 93, 1645-51	6.6	203

262	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1506-13	2.2	193
261	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , <b>2006</b> , 107, 4643-9	2.2	177
260	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , <b>2013</b> , 24, 561-76	10.3	162
259	Alteration of BIRC3 and multiple other NF- $\kappa$ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , <b>2011</b> , 118, 4930-4	2.2	151
258	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , <b>2002</b> , 99, 856-62	2.2	147
257	Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 169-77	13.4	145
256	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , <b>2011</b> , 117, 1595-604	2.2	145
255	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. <i>Blood</i> , <b>2012</b> , 119, 188-91	2.2	136
254	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. <i>Blood</i> , <b>2007</b> , 110, 485-9	2.2	131
253	Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5630-5	2.2	116
252	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , <b>2016</b> , 128, 2527-2532	2.2	115
251	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1404-1410	10.3	114
250	Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. <i>Blood</i> , <b>2011</b> , 118, 4591-4	2.2	114
249	Splenic marginal zone lymphoma: from genetics to management. <i>Blood</i> , <b>2016</b> , 127, 2072-81	2.2	106
248	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2108-12	10.3	104
247	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 319-331	21.7	103
246	Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjogren syndrome or hepatitis C virus infection. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 43-9	4.5	102
245	Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. <i>Cancer</i> , <b>2004</b> , 100, 107-15	6.4	101

244	A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. <i>Blood</i> , <b>2008</b> , 111, 3383-7	2.2	95
243	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , <b>2007</b> , 18, 346-50	10.3	95
242	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1362-73	2.2	88
241	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 735-44	4.5	88
240	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. <i>Blood</i> , <b>2005</b> , 105, 3428-33	2.2	88
239	Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. <i>Leukemia</i> , <b>2012</b> , 26, 1654-62	10.7	87
238	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 689-696	2.2	81
237	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2119-23	10.3	78
236	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2020</b> , 31, 17-29	10.3	77
235	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 2131-6	15.4	75
234	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , <b>2010</b> , 95, 1792-6	6.6	74
233	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. <i>Cancer</i> , <b>2006</b> , 107, 2206-11	6.4	74
232	Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1434-40	10.3	74
231	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 785-92	3.2	72
230	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 1145-1160	13.6	69
229	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6398-405	12.9	69
228	Leukemic transformation of polycythemia vera: a single center study of 23 patients. <i>Cancer</i> , <b>2005</b> , 104, 1032-6	6.4	67
227	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 523-541	13.6	66

226	Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 301-4	4.5	66
225	Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6487-93	12.9	64
224	The Kr��pel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , <b>2015</b> , 29, 503-7	10.7	62
223	Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 164-71	4.5	62
222	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. <i>Haematologica</i> , <b>2013</b> , 98, 635-9	6.6	60
221	Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. <i>Haematologica</i> , <b>2003</b> , 88, 13-8	6.6	60
220	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , <b>2019</b> , 133, 137-146	2.2	59
219	Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 295-301	3.2	56
218	The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. <i>British Journal of Haematology</i> , <b>1999</b> , 107, 877-82	4.5	55
217	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. <i>Haematologica</i> , <b>2011</b> , 96, 454-8	6.6	53
216	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , <b>2015</b> , 100, 246-52	6.6	51
215	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. <i>Oncologist</i> , <b>2006</b> , 11, 285-91	5.7	51
214	The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 536-44	3.4	51
213	A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2002</b> , 116, 229-35	4.5	48
212	Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 46-50	7.1	47
211	Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 638185		47
210	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , <b>2014</b> , 99, 489-96	6.6	46
209	Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. <i>Annals of Oncology</i> , <b>2009</b> , 20, 129-36	10.3	46

208	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. <i>Haematologica</i> , <b>2011</b> , 96, 167-70	6.6	45
207	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. <i>British Journal of Haematology</i> , <b>2008</b> , 140, 162-8	4.5	44
206	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , <b>2017</b> , 102, 2077-2085	6.6	43
205	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , <b>2015</b> , 125, 1922-31	2.2	40
204	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , <b>2013</b> , 122, 2284-5	2.2	40
203	Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1189-1195	10.3	39
202	Risk of second cancers in Waldenström macroglobulinemia. <i>Annals of Oncology</i> , <b>2012</b> , 23, 411-5	10.3	37
201	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. <i>Oncologist</i> , <b>2019</b> , 24, e720-e729	5.7	36
200	Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. <i>European Journal of Haematology</i> , <b>2009</b> , 83, 165-74	3.8	36
199	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1331-1335	10.3	35
198	From hepatitis C virus infection to B-cell lymphoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 92-100	10.3	34
197	Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6923-6932	4.8	34
196	B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. <i>Blood</i> , <b>2014</b> , 123, 1512-5	2.2	34
195	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 69-76	4.5	32
194	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 929-31	1.9	32
193	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. <i>Blood</i> , <b>2014</b> , 123, 1836-49	2.2	31
192	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 455-7	4.5	30
191	Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 719-21	4.5	29



190	Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2004</b> , 4, 250-2		29
189	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , <b>2016</b> , 5, 2740-2755	4.8	28
188	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. <i>Blood Cells, Molecules, and Diseases</i> , <b>2009</b> , 42, 286-91	2.1	26
187	Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy?. <i>European Journal of Applied Physiology</i> , <b>2007</b> , 99, 511-8	3.4	26
186	Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 2497-2506	3.9	26
185	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. <i>European Journal of Haematology</i> , <b>2010</b> , 85, 405-15	3.8	25
184	Marginal zone-related neoplasms of splenic and nodal origin. <i>Haematologica</i> , <b>2003</b> , 88, 80-93	6.6	25
183	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 75-85	2	24
182	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. <i>Blood</i> , <b>2018</b> , 132, 4-4	2.2	24
181	Overview on the management of non-gastric MALT lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , <b>2018</b> , 31, 57-64	4.2	24
180	Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1717-24	3	23
179	Circulating endothelial cells in COVID-19. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E187-E188	7.1	22
178	Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. <i>Annals of Hematology</i> , <b>2004</b> , 83, 495-7	3	22
177	Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives. <i>Journal of Hypertension</i> , <b>2001</b> , 19, 213-22	1.9	22
176	Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. <i>Current Clinical Pharmacology</i> , <b>2010</b> , 5, 74-81	2.5	22
175	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , <b>2019</b> , 134, 798-801	2.2	20
174	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2485-9	1.9	20
173	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. <i>Journal of Internal Medicine</i> , <b>2009</b> , 265, 266-74	10.8	20

172	Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 718-20	4.5	19
171	A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 34, 175-9	4.4	19
170	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , <b>2021</b> , 35, 787-795	10.7	19
169	Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?. <i>Therapeutic Advances in Hematology</i> , <b>2016</b> , 7, 94-107	5.7	18
168	Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 103-5	2	18
167	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. <i>Human Pathology</i> , <b>2009</b> , 40, 1628-37	3.7	18
166	Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. <i>Leukemia Research</i> , <b>2006</b> , 30, 277-82	2.7	18
165	Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19. <i>Scientific Reports</i> , <b>2020</b> , 10, 20836	4.9	18
164	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. <i>Hematological Oncology</i> , <b>2017</b> , 35, 296-302	1.3	16
163	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 435-9	4.5	15
162	Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 8447-8458	5.6	15
161	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , <b>2020</b> , 34, 1462-1466	10.7	15
160	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 371-377	4.5	15
159	Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E185-E188	7.1	14
158	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , <b>2019</b> , 37, 160-167	1.3	14
157	Everolimus in diffuse large B-cell lymphomas. <i>Future Oncology</i> , <b>2015</b> , 11, 373-83	3.6	14
156	mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in. <i>Haematologica</i> , <b>2018</b> , 103, e408-e411	6.6	14
155	Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 700-3	2	14



154	PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. <i>Hematological Oncology</i> , <b>2015</b> , 33, 125-32	1.3	14
153	CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. <i>Human Pathology</i> , <b>2011</b> , 42, 1204-8	3.7	14
152	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , <b>2019</b> , 185, 713-717	4.5	13
151	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. <i>Blood</i> , <b>2020</b> , 135, 293-296	2.2	13
150	Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. <i>Leukemia Research</i> , <b>2011</b> , 35, 712-4	2.7	13
149	B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution. <i>Transplantation</i> , <b>2006</b> , 82, 1013-23	1.8	13
148	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , <b>2018</b> , 103, 849-856	6.6	12
147	Novel agents in indolent lymphomas. <i>Therapeutic Advances in Hematology</i> , <b>2013</b> , 4, 133-48	5.7	12
146	Eosinophilic folliculitis occurring in a patient affected by Hodgkin lymphoma. <i>International Journal of Dermatology</i> , <b>2002</b> , 41, 298-300	1.7	12
145	Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2122-2128	1.9	11
144	Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. <i>Oncology</i> , <b>2005</b> , 68, 146-53	3.6	11
143	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 897-912	5.9	10
142	Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E152-3	7.1	10
141	Antiviral therapies for managing viral hepatitis in lymphoma patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 363-376	4	9
140	New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 767-80	2.8	9
139	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1193-1199	7.1	9
138	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 798-800	4.4	9
137	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e34-e44	14.6	9

136	Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas. <i>Hepatology</i> , <b>2017</b> , 66, 1341-1343	11.2	8
135	HCV infection and non-Hodgkin lymphomas: an evolving story. <i>Clinical and Experimental Medicine</i> , <b>2020</b> , 20, 321-328	4.9	8
134	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 880-7	1.9	8
133	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 807-815	4.5	8
132	Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 230-4	7.1	8
131	Prognostic assessment in patients with indolent B-cell lymphomas. <i>Scientific World Journal, The</i> , <b>2012</b> , 2012, 107892	2.2	8
130	Therapy-Related Late Adverse Events in Hodgkin Lymphoma. <i>Lymphoma</i> , <b>2013</b> , 2013, 1-7		8
129	Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e304-6	2.2	8
128	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes. <i>Human Pathology</i> , <b>2021</b> , 111, 1-9	3.7	8
127	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 224-235	4.5	8
126	Blast phase of essential thrombocythemia: A single center study. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 641-4	7.1	7
125	Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 2246-9	7.5	7
124	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , <b>2014</b> , 124, 705-705	2.2	7
123	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101234	2.2	7
122	Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report. <i>Annals of Hematology</i> , <b>2009</b> , 88, 379-81	3	6
121	Validation of cytogenetic-based risk stratification in primary myelofibrosis. <i>Blood</i> , <b>2010</b> , 115, 2719-20	2.2	6
120	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. <i>Leukemia</i> , <b>2005</b> , 19, 888-9	10.7	6
119	Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas. <i>European Journal of Applied Physiology</i> , <b>2000</b> , 83, 481-6	3.4	6

118	Rituximab maintenance in follicular lymphoma patients. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 281-8.5	6
117	Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2968-2974	1.9 5
116	Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 301-2	4.5 5
115	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , <b>2020</b> , 4, e302	0.3 5
114	Benefits and risks of JAK inhibition. <i>Blood</i> , <b>2018</b> , 132, 675-676	2.2 5
113	Diagnosis and management of prefibrotic myelofibrosis. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 537-545.8	5
112	A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 441-446	4.5 5
111	Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 182-6	12.9 5
110	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 805-7	1.9 5
109	Role of the molecular staging and response in the management of follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1018-22	1.9 5
108	Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse. <i>British Journal of Haematology</i> , <b>2000</b> , 109, 895-6	4.5 5
107	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. <i>Blood</i> , <b>2011</b> , 118, 261-261	2.2 5
106	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , <b>2015</b> , 126, 3938-3938	2.2 5
105	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2021</b> ,	2.2 5
104	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , <b>2019</b> , 3, 1-15	5.2 5
103	Validation of a new prognostic body composition parameter in cancer patients. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 615-623	5.9 5
102	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , <b>2015</b> , 100, 517-24	6.6 4
101	Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e543-5	2.2 4

100	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. <i>ESMO Open</i> , <b>2022</b> , 7, 100403	6	4
99	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , <b>2021</b> ,	7.8	4
98	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. <i>Blood Advances</i> , <b>2020</b> , 4, 1013-1019	7.8	4
97	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , <b>2018</b> , 23, 1033-1038	5.7	3
96	Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications. <i>Hematological Oncology</i> , <b>2018</b> , 36, 723-732	1.3	3
95	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 56-61	7.1	3
94	Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario o recidivante. <i>Pharmacoeconomics Italian Research Articles</i> , <b>2007</b> , 9, 9-19		3
93	An insidious presentation of splenic marginal zone lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 432-3		3
92	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , <b>2015</b> , 126, 3946-3946	2.2	3
91	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8006-8006	2.2	3
90	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. <i>Hematological Oncology</i> , <b>2020</b> , 38, 689-697	1.3	3
89	Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. <i>Leukemia</i> , <b>2021</b> , 35, 1490-1493	10.7	3
88	Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Hematological Oncology</i> , <b>2020</b> , 38, 554-559	1.3	2
87	Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 883-4	4	2
86	A paraumbilical lymphomatous mass. <i>European Journal of Haematology</i> , <b>2006</b> , 77, 180	3.8	2
85	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , <b>2018</b> , 132, 922-922 <sup>2,2</sup>		2
84	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. <i>Blood</i> , <b>2005</b> , 106, 791-791	2.2	2
83	Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIb MAXIMA Study. <i>Blood</i> , <b>2010</b> , 116, 3945-3945	2.2	2

82	Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical, Immunohistochemical and Molecular Evaluation of 23 Cases with Primary Cutaneous Involvement,. <i>Blood</i> , <b>2011</b> , 118, 3565-3565	2.2	2
81	Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era. <i>Blood</i> , <b>2015</b> , 126, 5098-5098	2.2	2
80	Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 4186-4186	2.2	2
79	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. <i>Blood</i> , <b>2016</b> , 128, 2928-2928	2.2	2
78	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , <b>2020</b> , 80, 219-224	18.9	2
77	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1473-1478	7.1	2
76	Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis. <i>Hematological Oncology</i> , <b>2021</b> , 39, 589-592	1.3	2
75	Dulanermin in indolent lymphomas: an ineffective approach. <i>Lancet Haematology,the</i> , <b>2015</b> , 2, e136-7	14.6	1
74	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	1
73	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis From the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , <b>2018</b> , 132, 393-393	2.2	1
72	The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.. <i>Blood</i> , <b>2007</b> , 110, 4475-4475	2.2	1
71	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. <i>Blood</i> , <b>2008</b> , 112, 1775-1775	2.2	1
70	Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.. <i>Blood</i> , <b>2009</b> , 114, 3951-3951	2.2	1
69	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , <b>2010</b> , 116, 1371-1371	2.2	1
68	Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. <i>Blood</i> , <b>2011</b> , 118, 1583-1583	2.2	1
67	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. <i>Blood</i> , <b>2011</b> , 118, 262-262	2.2	1
66	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. <i>Blood</i> , <b>2012</b> , 120, 2720-2720	2.2	1
65	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , <b>2013</b> , 122, 3049-3049	2.2	1



64	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , <b>2015</b> , 126, 1486-1486	2.2	1
63	Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. <i>Blood</i> , <b>2015</b> , 126, 821-821	2.2	1
62	Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi. <i>Blood</i> , <b>2018</b> , 132, 2066-2066	2.2	1
61	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , <b>2014</b> , 124, 2526-2526	2.2	1
60	Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8547-8547	2.2	1
59	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , <b>2010</b> , 116, 1784-1784	2.2	1
58	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstrom Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. <i>Blood</i> , <b>2012</b> , 120, 2667-2667	2.2	1
57	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The Rete Ematologica Lombarda/Hematology Network Of Lombardia Region <i>Blood</i> , <b>2013</b> , 122, 3003-3003	2.2	1
56	Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 726637	5.3	1
55	Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer. <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	1
54	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2020</b> , 136, 16-17	2.2	0
53	Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib. <i>Blood</i> , <b>2019</b> , 134, 1660-1660	2.2	0
52	Hodgkin Lymphoma With Diplopia and Nystagmus: A Paraneoplastic Cerebellar Degeneration With Ectopic Expression of DNER Antigen on Reed-Sternberg Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	2	0
51	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. <i>Blood</i> , <b>2018</b> , 132, 2026-2026	2.2	0
50	Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. <i>Blood</i> , <b>2015</b> , 126, 2686-2686	2.2	0
49	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E210-E214	7.1	0
48	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1643-1649	4	0
47	Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas. <i>Hematological Oncology</i> , <b>2021</b> , 39, 263-266	1.3	0



46	Late-onset EBV-related post-transplant non-secreting plasma-cell neoplasms: Description of two cases. <i>Leukemia Research</i> , <b>2021</b> , 100, 106493	2.7	0
45	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2350-2353	4.4	
44	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 896-9	4.5	
43	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. <i>Hematological Oncology</i> , <b>2017</b> , 35, 145-146 <sup>1,3</sup>		
42	DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , <b>2017</b> , 35, 194-196 <sup>1,3</sup>		
41	Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	
40	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIb Study.. <i>Advances in Hematology</i> , <b>2022</b> , 2022, 5581772	1.5	
39	Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases. <i>Blood</i> , <b>2021</b> , 138, 1434-1434	2.2	
38	The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Related Non-Hodgkin Lymphoma: An Update of a Multicenter Study.. <i>Blood</i> , <b>2005</b> , 106, 1509-1509	2.2	
37	Clinical Features and Outcome of 147 Patients with Diffuse Large B-Cell Lymphoma and Hepatitis C Virus Infection.. <i>Blood</i> , <b>2005</b> , 106, 1921-1921	2.2	
36	Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders.. <i>Blood</i> , <b>2006</b> , 108, 2682-2682	2.2	
35	High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.. <i>Blood</i> , <b>2007</b> , 110, 2620-2620	2.2	
34	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients <b>2018</b> , 1-15		
33	Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR). <i>Blood</i> , <b>2018</b> , 132, 2266-2266	2.2	
32	Hepatitis B Virus Associated B-Cell Non-Hodgkin Lymphoma in Non-Endemic Areas. <i>Blood</i> , <b>2018</b> , 132, 4228-4228	2.2	
31	ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center. <i>Creative Nursing</i> , <b>2019</b> , 25, 157-168	0.6	
30	Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis. <i>Blood</i> , <b>2019</b> , 134, 1502-1502	2.2	
29	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients <b>2020</b> , 567-581		

- 28 Indolent Lymphomas: Follicular Lymphoma, HVC-Associated Marginal Zone B-Cell Lymphoma, and Waldenström Macroglobulinemia **2015**, 245-252
- 27 Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. *Blood*, **2015**, 126, 701-701<sup>2,2</sup>
- 26 Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. *Blood*, **2015**, 126, 5084-5084 2.2
- 25 Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. *Blood*, **2016**, 128, 2978-2978 2.2
- 24 Peripheral Stem Cell Mobilization with Chemotherapy + G-CSF Priming in a Large Series of Patients with Lymphoma Candidates to Autologous Transplantation. An Analysis of Baseline and Ongoing Predictors of Failure or Suboptimal Stem Cell Collection.. *Blood*, **2009**, 114, 2149-2149 2.2
- 23 INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia.. *Blood*, **2009**, 114, 2905-2905 2.2
- 22 Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. *Blood*, **2009**, 114, 760-760 2.2
- 21 The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. *Blood*, **2010**, 116, 3601-3601 2.2
- 20 Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients. *Blood*, **2010**, 116, 2876-2876 2.2
- 19 The NF- $\kappa$ B Pathway Is Targeted by Multiple Genetic Lesions In Splenic Marginal Zone Lymphoma. *Blood*, **2010**, 116, 4169-4169 2.2
- 18 The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. *Blood*, **2011**, 118, 2651-2651 2.2
- 17 SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). *Blood*, **2011**, 118, 263-263
- 16 Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. *Blood*, **2011**, 118, 2636-2636 2.2
- 15 Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. *Blood*, **2011**, 118, 1359-1359 2.2
- 14 Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. *Blood*, **2012**, 120, 2657-2657 2.2
- 13 Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma. *Blood*, **2012**, 120, 1585-1585 2.2
- 12 What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study Refol by the Fondazione Italiana Linfomi (FIL) On 548 Patients. *Blood*, **2012**, 120, 154-154 2.2
- 11 Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). *Blood*, **2012**, 120, 3653-3653 2.2

10	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , <b>2013</b> , 122, 1782-1782	2.2
9	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. <i>Blood</i> , <b>2013</b> , 122, 77-77	2.2
8	Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma <b>2014</b> , 253-276	
7	Direct-acting antiviral agents in lymphoproliferative disorders: more complex than expected. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 661-662	4.5
6	Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 11-12	4.5
5	Nodal Marginal Zone Lymphoma. <i>Hematologic Malignancies</i> , <b>2021</b> , 117-125	0
4	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1782-1785	1.9
3	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3311-3312	1.9
2	Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E404-E408	7.1
1	Reply to M. Shibusawa et al.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200177	2.2